Prothena | PRTA - Net Income


Prothena reported $32.72M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 501K 66.98M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Exelixis USD 212.05M 1.58M Jun/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Prothena USD 32.72M 54.31M Mar/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026